The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
A gadolinium-based, hydrophilic, macrocyclic, electrically
neutral contrast agent used in contrast-enhanced MRI (CE-MRI).
Gadobutrol is a non-ionic, paramagnetic complex consisting of
gadolinium (Gd3+) chelated with the macrocyclic compound
(butrol). Following intravenous administration, gadobutrol may increase
MRI sensitivity for the detection of tumors and inflammatory and
demyelinating diseases of the central nervous system (CNS) which are
associated with areas with blood-brain
barrier defects due to altered perfusion or an enlarged extracellular
space. This agent is eliminated in an unchanged form via the kidneys;
extra-renal elimination is negligible.
The term "gadobutrol" was found in the following pages: